Search results
For over 35 years Parexel has been a trusted global CRO and biopharmaceutical services company. Learn more about how we can help.
- Careers
Transform healthcare, trial new treatments, and reinvent...
- 日本
Parexel...
- Contact Us
Need to expedite your development journey? Parexel is here...
- Biotech Solutions
At Parexel Biotech, we’ve integrated our wide breadth of...
- Volunteer
(Xoli Belgrave): For us here at Parexel, the involvement of...
- Early Development and Innovation
At Parexel, we’re perfectly positioned with fully integrated...
- FSP Delivery Models
At Parexel, we're very proud that our FSP partnerships are...
- Integrated Clinical Development
At Parexel, we combine a comprehensive portfolio of medical...
- Careers
Parexel International is an American provider of biopharmaceutical services. It conducts clinical trials on behalf of its pharmaceutical clients to expedite the drug approval process.
Parexel is a global CRO that provides clinical development services to biopharmaceutical companies and sites. Learn about its values, awards, brands, and how it designs solutions with patients in mind.
Transform healthcare, trial new treatments, and reinvent medicine to change patients’ lives – and do it With Heart. Explore careers with Parexel today.
Parexel is a clinical research organization that provides services for biopharmaceutical and biotech companies. Follow its LinkedIn page to see updates, events, insights and opportunities in the industry.
Whatever the size of your biopharmaceutical company, our global presence can help accelerate your drug development around the world. Our diverse professionals represent the best and the brightest in clinical, regulatory and market access specialties.
12 sie 2024 · Parexel Releases 2023 Environmental, Social and Governance Report. Parexel's ESG Report is part of its annual commitment to disclose and communicate the progress of its sustainability priorities, underscoring the company’s core values of putting Patients First and delivering With Heart™. Read More. April 25, 2024.
